Last updated on Wednesday, 31 May 2017

Christus St Vincent Regional Cancer Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011401SupportiveOpen Active2016-09-29Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
UNM 1523SupportiveOpen Active2016-09-21INST UNM 1523: Implementing an Evidence-Based Oral Care Protocol in Head and Neck Patients Receiving Radiation Therapy
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2017-03-21ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
SWOG S1403Lung NSCLC AdvancedOpen Active2017-03-14SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-12-19ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1609Ill DefinedOpen Active2017-05-26SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG S1216GU Prostate AdvancedOpen Active2013-08-01SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
SWOG S1513GI Pancreatic AdvancedOpen Active2017-01-11SWOG S1513: Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1416Breast AdvancedOpen Active2016-11-03SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
ECOG E2112Breast AdvancedOpen Active2016-03-10ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
NSABP B-51Breast AdjuvantOpen Active2017-01-24NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-11-03ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance A011202Breast AdjuvantOpen Active2017-03-17Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
SWOG S1207Breast AdjuvantOpen Active2016-03-09SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S9808AdministrativeOpen Active2014-07-09SWOG S9808 - Long Term Follow-up Protocol: An Administrative Tool

Lovelace Cancer Care

Trial #TypeStudy StatusStatus DateTitle
Alliance A011401SupportiveOpen Active2016-09-17Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-12ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-12ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
S1400GLung SCLC AdvancedOpen Active2017-05-03SWOG S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400ILung SCLC AdvancedOpen Active2017-02-13SWOG S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
SWOG S1400Lung OtherOpen Active2017-02-13SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Pharm CA209568Lung NSCLC AdvancedOpen Active2017-05-09Bristol-Myers Squibb CA209568: A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
SWOG S1403Lung NSCLC AdvancedOpen Active2017-03-14SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-12ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
INST 96144Ill DefinedOpen Active2015-07-28INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1216GU Prostate AdvancedOpen Active2015-06-09SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
SWOG S1416Breast AdvancedOpen Active2016-09-26SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Pharm CLEE011A2404Breast AdvancedOpen Active2017-05-18Novartis CLEE011A2404: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
NSABP B-55/BIG 6-13Breast AdjuvantOpen Active2017-05-25NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
SWOG S1207Breast AdjuvantOpen Active2015-06-09SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-08-01ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
NSABP B-51Breast AdjuvantOpen Active2017-04-13NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance A011202Breast AdjuvantOpen Active2016-08-27Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
National Cancer Prevention DCP-001SupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Alliance A011401SupportiveOpen Active2016-12-16Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN E1Q11SupportiveOpen Active2016-12-19ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2017-04-26ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
SWOG S1400ILung SCLC AdvancedOpen Active2017-02-13SWOG S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
S1400GLung SCLC AdvancedOpen Active2017-05-03SWOG S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400Lung OtherOpen Active2017-02-13SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
SWOG S1403Lung NSCLC AdvancedOpen Active2017-03-14SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2017-03-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-04-21ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
NCI 9671Ill DefinedOpen Active2015-07-21NCI 9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
SWOG S1609Ill DefinedOpen Active2017-04-24SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2017-03-27ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
ECOG-ACRIN E1A11Hematology MyelomaOpen Active2016-11-07ECOG ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Pharm ICT-8Hematology Acute LeukemiaOpen Active2017-04-21Hybrigenics S.A. ICT-8: Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
GOG 0213GYN Ovarian AdvancedOpen Active2010-06-25GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2017-04-28NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
NRG Oncology NRG-GY005GYN OtherOpen Active2017-04-28NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
GOG 0274GYN Cervical AdvancedOpen Active2016-02-26GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0924GU Prostate AdvancedOpen Active2015-08-04RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
SWOG S1216GU Prostate AdvancedOpen Active2013-07-30SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-12-16SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
ECOG E2112Breast AdvancedOpen Active2014-09-03ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
NSABP B-51Breast AdjuvantOpen Active2017-01-26NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1207Breast AdjuvantOpen Active2013-11-01SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
SWOG S9808AdministrativeOpen Active2014-09-03SWOG S9808 - Long Term Follow-up Protocol: An Administrative Tool

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2017-04-26ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2017-03-21ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
SWOG S1400ILung SCLC AdvancedOpen Active2017-02-13SWOG S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
S1400GLung SCLC AdvancedOpen Active2017-05-03SWOG S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400Lung OtherOpen Active2017-02-13SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Pharm CA209568Lung NSCLC AdvancedOpen Active2017-05-09Bristol-Myers Squibb CA209568: A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
SWOG S1403Lung NSCLC AdvancedOpen Active2017-03-14SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
RTOG 1306Lung NSCLC AdvancedOpen Active2015-12-18RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-17ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1609Ill DefinedOpen Active2017-04-24SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144Ill DefinedOpen Active2014-12-09INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-10-26ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Pharm PrTK03GU Prostate AdjuvantOpen Active2016-02-23Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
SWOG S1513GI Pancreatic AdvancedOpen Active2017-01-11SWOG S1513: Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Pharm CLEE011A2404Breast AdvancedOpen Active2017-05-18Novartis CLEE011A2404: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
NRG-BR002Breast AdvancedOpen Active2017-05-04NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
ECOG E2112Breast AdvancedOpen Active2015-04-20ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-08-30SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-10-20NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
SWOG S1207Breast AdjuvantOpen Active2015-04-14SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
SWOG S9808AdministrativeOpen Active1998-09-12SWOG S9808 - Long Term Follow-up Protocol: An Administrative Tool

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2017-03-21ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2017-04-26ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2017-04-17ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
INST 1211SupportiveOpen Active2016-05-24INST 1211: A Pilot Randomized Placebo-Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
Alliance A011401SupportiveOpen Active2016-11-01Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
Pharm CLEE011A2404Breast AdvancedOpen Active2017-05-18Novartis CLEE011A2404: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
SWOG S1417CDCCDROpen Active2017-05-26SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool
in Patients with Metastatic Colorectal Cancer
SWOG S1513GI Pancreatic AdvancedOpen Active2017-02-06SWOG S1513: Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Pharm A041-04GU Renal Cell AdvancedOpen Active2015-08-03Acceleron A041-04: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma
INST 96144Ill DefinedOpen Active2013-06-04INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2017-04-24SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-04-21ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Pharm CA209568Lung NSCLC AdvancedOpen Active2017-05-09Bristol-Myers Squibb CA209568: A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-PMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-P: MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2017-04-17ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
SWOG S1207Breast AdjuvantOpen Active2013-04-08SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
INST 2014-0443Breast AdjuvantOpen Active2015-04-02MD Anderson Cancer Center 2014-0443: Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-08Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
SWOG S9808AdministrativeOpen Active2014-07-09SWOG S9808 - Long Term Follow-up Protocol: An Administrative Tool

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-29ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-07-06ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Pharm CA209568Lung NSCLC AdvancedOpen Active2017-05-09Bristol-Myers Squibb CA209568: A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2017-04-26ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
SWOG S1404Skin Melanoma AdvancedOpen Active2017-03-01SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG 0274GYN Cervical AdvancedOpen Active2012-07-30GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
NRG Oncology NRG-GY002GYN Cervical AdvancedOpen Active2016-05-03NRG Oncology NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
GOG-0286BGYN Endometrial AdvancedOpen Active2017-01-10GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NRG Oncology NRG-GY005GYN OtherOpen Active2017-04-28NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2017-04-28NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Pharm 0403GYN Ovarian AdvancedOpen Active2017-05-26ImmunoGen 0403: FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the
Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0213GYN Ovarian AdvancedOpen Active2009-09-01GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
INST CR1303GYN Ovarian AdvancedOpen Active2013-07-30(IRB EXEMPT) INST CR1303: Magnesium Levels in Ovarian Cancer Patients Undergoing Taxol and Platinum Based Chemotherapy and the Correlation with Neuropsychologic Outcomes via FACT Quality of Life Scores
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
UNM 1605SupportiveOpen Active2017-05-01INST UNM 1605: Biobehavioral Effects of Tai Chi Qigong for Prostate Cancer Survivors with Fatigue
ECOG-ACRIN E1Q11SupportiveOpen Active2016-07-15ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
UNM 1520SupportiveOpen Active2016-04-05INST UNM 1520: Replacing Sedentary Time with Light Activity
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
INST 1211SupportiveOpen Active2016-05-24INST 1211: A Pilot Randomized Placebo-Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
INST 0811SupportiveOpen Active2008-06-23(IRB EXEMPT) INST 0811: Pelvic Floor Disorder and Sexual Dysfunction in Gynecologic Cancer Survivors compared with Routine Gynecologic Patients
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2017-01-18ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2017-04-26ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Pharm TLPLDCSkin Melanoma AdvancedOpen Active2017-04-04Cancer Insight TLPLDC: A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (resected) Melanoma to Prevent Recurrence
Pharm TRX518-003Solid Tumors OtherOpen Active2016-09-28Leap Therapeutics. Inc TRX518-003: A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
Pharm BXQ-350.AASolid Tumors OtherOpen Active2016-11-30Bexion BXQ-350.AA: Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas
Pharm 2455-001Solid Tumors OtherOpen Active2016-09-21Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in
Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2017-01-18ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2017-01-18ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
INST 1212Skin Melanoma AdvancedOpen Active2013-04-17(IRB EXEMPT) INST 1212: PTEN Status and Nodal Metastasis in Melanoma
COG ALTE11C2SupportiveOpen Active2014-03-13COG ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
COG ALTE11C1SupportiveOpen Active2014-03-13COG ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Alliance A011401SupportiveOpen Active2016-10-02Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
INST CUTISupportiveOpen Active2017-04-28INST CUTI: Cancer of the Uterus and Treatment of Stress Urinary Incontinence (CUTI)
Pharm CTIX-BRI-205SupportiveOpen Active2017-04-18Cellceutix Corp. CTIX-BRI-205: Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients with Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy
Alliance A091202Sarcoma AdvancedOpen Active2016-10-01Alliance A091202: A Phase II, Randomized, Double Blinded Study Of The Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone Vs. Placebo In Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Alliance A091304Sarcoma AdvancedOpen Active2017-04-27Alliance A091304: A Phase I/Randomized Phase II study of MLN0128 vs. Pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma
COG AOST1321Sarcoma AdvancedOpen Active2016-06-28COG AOST1321: Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, forRecurrent or Refractory Osteosarcoma
COG D9902Sarcoma AncillaryOpen Active2001-06-20COG D9902: A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
COG AOST06B1Sarcoma AncillaryOpen Active2008-04-10COG AOST06B1: A Childrens Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
Pharm NLG-2103Skin Melanoma AdvancedOpen Active2016-09-13NewLink Genetics NLG-2103: A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Ipilimumab for Adult Patients with Metastatic Melanoma
ECOG-ACRIN EA6141Skin Melanoma AdvancedOpen Active2017-03-21ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma
SWOG S1404Skin Melanoma AdvancedOpen Active2017-03-01SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2017-01-18ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2017-01-18ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
Pharm MK-3475 PN158Solid Tumors OtherOpen Active2016-07-21Merck MK3475 PN158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Pharm 0761-014Solid Tumors OtherOpen Active2016-09-20Kyowa Hakko Kirin 0761-014: Open-label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
COG LTFPediatricOpen Active2003-01-07COG LTF: A Groupwide Procedure for Collecting Long Term Follow Up Data
COG AREN03B2PediatricOpen Active2006-05-18COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study
COG ALTE03N1PediatricOpen Active2004-07-09COG ALTE03N1: Key Adverse Events After Childhood Cancer
COG AHOD1331PediatricOpen Active2015-05-29COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
COG ALTE07C1PediatricOpen Active2009-02-03COG ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
COG ACNS02B3PediatricOpen Active2010-12-06COG ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
COG ALTE05N1PediatricOpen Active2008-07-21COG ALTE05N1: Umbrella Long-Term Follow-Up Protocol
INST 1306Ill DefinedOpen Active2015-01-01INST 1306: Whole Genome Sequencing of Human Cancer Tissues
COG ANBL00B1Ill DefinedOpen Active2001-07-11COG ANBL00B1: Neuroblastoma Biology Study
COG ANBL0032Ill DefinedOpen Active2009-04-30COG ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
COG ACCRN07Ill DefinedOpen Active2008-02-12COG ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
NRG Oncology RTOG 0631Ill DefinedOpen Active2017-02-24NRG Oncology RTOG 0631: Phase 2/3 Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
SWOG S1316Ill DefinedOpen Active2017-03-27SWOG S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
INST 1405Ill DefinedOpen Active2014-06-26(IRB EXEMPT) INST 1405: Evaluation of the Hispanic Cancer 101
SWOG S1609Ill DefinedOpen Active2017-04-24SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2017-03-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2016-05-09ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A081105Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A081105: RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Pharm 265-109Lung NSCLC AdvancedOpen Active2016-02-10Mirati Therapeutics 265-109: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Pharm I3Y-MC-JPBJLung NSCLC AdvancedOpen Active2014-08-25Eli Lilly I3Y-MC-JPBJ: A Phase 1b Study of LY2835219 in Combination with Multiple Single-Agent Options for Patients with Stage IV NSCLC
RTOG 1306Lung NSCLC AdvancedOpen Active2015-12-18RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Pharm CA209568Lung NSCLC AdvancedOpen Active2017-05-09Bristol-Myers Squibb CA209568: A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
SWOG S1403Lung NSCLC AdvancedOpen Active2017-03-14SWOG S1403: A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
SWOG S1400Lung OtherOpen Active2017-02-13SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
NRG Oncology NRG-CC003Lung SCLC AdjuvantOpen Active2016-08-17NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
CALGB 30610Lung SCLC AdjuvantOpen Active2013-10-29CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
SWOG S1400ILung SCLC AdvancedOpen Active2017-02-13SWOG S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
S1400GLung SCLC AdvancedOpen Active2017-05-03SWOG S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2017-01-18ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
COG ACCL1033Hematology Acute LeukemiaOpen Active2012-11-13COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
COG AAML1031Hematology Acute LeukemiaOpen Active2016-04-11COG AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
COG AALL1131Hematology Acute LeukemiaOpen Active2012-03-01COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
UNM 1503Hematology Acute LeukemiaOpen Active2016-07-28INST UNM 1503: Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
SWOG S1318Hematology Acute LeukemiaOpen Active2017-01-25SWOG S1318: A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients
COG AALL06N1Hematology Acute LeukemiaOpen Active2009-01-06COG AALL06N1: A Study of Neurocognitive Function in Children Treated for ALL: (A Groupwide, Non-therapeutic Companion Study to AALL0232 and AALL0434)
COG AALL05B1Hematology Acute LeukemiaOpen Active2006-12-12COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
HRRC #03-183Hematology Acute LeukemiaOpen Active2008-01-22HRRC #03-183: Biological Correlates with T-ALL Gene Expression and Clinical Outcome
COG AAML08B1Hematology Acute LeukemiaOpen Active2009-06-08COG AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
SWOG S0919Hematology Acute LeukemiaOpen Active2015-08-12SWOG S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia
COG AALL08B1Hematology Acute LeukemiaOpen Active2010-10-15COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Pharm ICT-8Hematology Acute LeukemiaOpen Active2017-04-21Hybrigenics S.A. ICT-8: Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
Pharm ImmunoGen 0601Hematology Acute LeukemiaOpen Active2017-01-11ImmunoGen 0601: A Phase I, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD-33-positive Acute Myeloid Leukemia
Pharm CNTX-CX-01-2015-AML-1Hematology Acute LeukemiaOpen Active2017-02-14Cantex Pharmaceuticals CNTX-CX-01-2015-AML-1: A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Pharm IPH2201Hematology Chronic LeukemiaOpen Active2016-05-17Innate IPH2201: Open Label Ib/IIa Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or previously untreated Chronic Lymphocytic Leukemia
COG AHOD04B1Hematology Lymphoma HodgkinsOpen Active2006-12-12COG AHOD04B1: Hodgkin Disease (HD) Banking Study
COG AALL1231Hematology Lymphoma Non-HodgkinsOpen Active2015-02-17COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Pharm D4190C00023Hematology Lymphoma Non-HodgkinsOpen Active2017-02-20MedImmune D4190C00023: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharm GO29365Hematology Lymphoma Non-HodgkinsOpen Active2016-02-29Genentech GO29365: A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCD S4501A) in Combination with Rituximab (R) or Obinutuxumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
COG ANHL12P1Hematology Lymphoma Non-HodgkinsOpen Active2014-03-13COG ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
ECOG E3A06Hematology MyelomaOpen Active2016-07-20ECOG E3A06: Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
ECOG-ACRIN E1A11Hematology MyelomaOpen Active2016-06-26ECOG ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Alliance A061202Hematology MyelomaOpen Active2017-05-17Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
INST H-25667Hematology OtherOpen Active2012-08-25INST H-25667: The Molecular Basis of Histiocytic Diseases
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2016-10-06ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
Pharm Onconova 04-30Hematology OtherOpen Active2016-04-14Onconova Therapeutics 04-30: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician
Pharm SGN33A-004Hematology OtherOpen Active2016-05-17Seattle Genetics SGN33A-004: A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High-risk Myelodysplastic Syndrome (MDS)
COG ABTR01B1Ill DefinedOpen Active2010-12-01COG ABTR01B1: A Childrens Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
INST 1101Ill DefinedOpen Active2011-03-30INST 1101: Investigating Cancer-Related Information Processing of Patients and Family Members
COG ANBL1221Ill DefinedOpen Active2016-08-01COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Pharm 516-001Ill DefinedOpen Active2016-02-05Mirati, Inc. 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
NCI 9671Ill DefinedOpen Active2015-07-06NCI 9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients who are Exceptional Responders
Pharm Eli Lilly I3Y-MC-JPBOIll DefinedOpen Active2016-07-01Eli Lilly I3Y-MC-JPBO: A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
INST CR1203GI Hepatic AdvancedOpen Active2012-06-11(IRB EXEMPT) INST CR1203: Major Hepatobiliary and Pancreatic Surgery for Cancer: Is age an independent risk factor?
UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
INST CR1301GI OtherOpen Active2013-06-23(IRB EXEMPT) INST CR1301: Clinicopathologic Correlations of Gallbladder Cancer by Ethnicity in New Mexico, 1980-2012: A Retrospective Chart Review
SWOG S1513GI Pancreatic AdvancedOpen Active2017-01-20SWOG S1513: Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
COG 9442GU OtherOpen Active1997-12-12COG 9442: National Wilms Tumor Late Effect Study
SWOG S1500GU OtherOpen Active2017-03-23SWOG S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC#749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Pharm PrTK03GU Prostate AdjuvantOpen Active2015-07-07Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
SWOG S1216GU Prostate AdvancedOpen Active2013-07-30SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
Pharm INO-VT-464-CL-003GU Prostate AdvancedOpen Active2016-10-04Innocrin Pharmaceuticals INO-VT-464-CL-003: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Pharm RX-0201-P2-A-09GU Renal Cell AdvancedOpen Active2016-08-03Rexahn RX-0201-P2-A-09: A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma
Pharm A041-04GU Renal Cell AdvancedOpen Active2015-05-06Acceleron A041-04: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Pharm GU14-182GU Ureter AdvancedOpen Active2016-09-28Hoosier Cancer Research Network GU14-182: A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-07-23RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG 0274GYN Cervical AdvancedOpen Active2012-06-28GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
GOG-0286BGYN Endometrial AdvancedOpen Active2017-01-10GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NRG Oncology NRG-GY005GYN OtherOpen Active2017-04-28NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
UNM 1509GYN OtherOpen Active2015-12-02INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2017-04-28NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Pharm 0403GYN Ovarian AdvancedOpen Active2017-05-26ImmunoGen 0403: FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the
Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator
INST CR1204GYN Ovarian AdvancedOpen Active2012-12-21INST CR1204: Pilot Study of Ketorolac and Ovarian Cancer Survival
GOG 0213GYN Ovarian AdvancedOpen Active2008-02-26GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
INST CR1303GYN Ovarian AdvancedOpen Active2013-07-30(IRB EXEMPT) INST CR1303: Magnesium Levels in Ovarian Cancer Patients Undergoing Taxol and Platinum Based Chemotherapy and the Correlation with Neuropsychologic Outcomes via FACT Quality of Life Scores
INST 1420GYN Ovarian NeoadjuvantOpen Active2015-10-29INST 1420: A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-12-14ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
RTOG 1008Head And Neck AdjuvantOpen Active2017-01-13RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
INST 1008Head And Neck AdvancedOpen Active2014-12-11INST 1008: Expression and Epigenetic Silencing of MicroRNA for Predicting the Therapeutic Response and Prognosis of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
ECOG E3311Head And Neck AdvancedOpen Active2016-04-05ECOG E3311: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
NRG Oncology NRG-HN003Head And Neck AdvancedOpen Active2017-04-27NRG Oncology NRG-HN003: A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
RTOG 0920Head And Neck AdvancedOpen Active2010-07-13RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
COG AALL0932Hematology Acute LeukemiaOpen Active2010-10-16COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
INST 1409Brain AdvancedOpen Active2016-03-09INST 1409: Single Center, Phase II Study of Whole Brain Radiation Using IMRT to Spare the Hippocampus while Delivering Differential Doses to Subclinical Sites versus Gross Disease for Treatment of Patients with Brain Metastases
INST 2014-0443Breast AdjuvantOpen Active2015-07-13MD Anderson Cancer Center 2014-0443: Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Alliance A011202Breast AdjuvantOpen Active2016-03-02Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03Breast AdjuvantOpen Active2016-05-13Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2016-07-16ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2017-03-30SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and
Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-08-01NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
SWOG S1207Breast AdjuvantOpen Active2013-03-26SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
NSABP B-55/BIG 6-13Breast AdjuvantOpen Active2017-05-25NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
INST CR1108Breast AdvancedOpen Active2011-07-05(IRB EXEMPT) INST CR1108: Characterization of Local Recurrence Rates After Breast Conservation Therapy (BCT) and Mastectomy, with Evaluation of Rates of Choice of BCT, Stage at Diagnosis by Urban vs Rural Status and Ethnicity in the Modern Era
RTOG 1119Breast AdvancedOpen Active2016-10-06RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer
INST 1302Breast AdvancedOpen Active2013-04-02INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study)
NRG-BR002Breast AdvancedOpen Active2016-04-07NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Pharm CLEE011A2404Breast AdvancedOpen Active2017-02-20Novartis CLEE011A2404: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
ECOG E2112Breast AdvancedOpen Active2014-06-03ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
SWOG S1416Breast AdvancedOpen Active2016-09-26SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Alliance A011106Breast NeoadjuvantOpen Active2016-09-15Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alliance A221405, IBCSG 48-14, BIG 8-13Breast OtherOpen Active2016-10-13Alliance A221405, IBCSG 48-14, BIG 8-13: POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer
UNM 1525Breast PreventionOpen Active2016-09-22INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study)
SWOG S1417CDCCDROpen Active2016-12-14SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool
in Patients with Metastatic Colorectal Cancer
UNM 1528EpidemiologicalOpen Active2016-04-01INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science
UNM 1602EpidemiologicalOpen Active2016-07-01INST UNM 1602: Genetic Risk Assessment for Education and Empowerment (GRACE): Intervention Pilot Study
UNM 1519EpidemiologicalOpen Active2016-08-26INST UNM 1519: Pilot Study for a Cancer Epidemiology Cohort of Ovarian, Endometrial, Bladder and Kidney Cancer Patients
COG AEWS07B1EpidemiologicalOpen Active2008-03-21COG AEWS07B1: A COG Study for Collecting and Banking Ewing Sarcoma Specimens
INST CR1112EpidemiologicalOpen Active2011-08-08(IRB EXEMPT) INST CR1112: Retrospective Analysis of Patients with Gastric, Small Bowel, Appendiceal, or Colorectal Malignancies Receiving G-CSF Versus No G-CSF While Undergoing Chemotherapy Treatment in the CRTC from 2003-2008
NCCTG N1048GI Colorectal AdvancedOpen Active2013-02-13NCCTG N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
INST 1303GI Colorectal AdvancedOpen Active2013-06-27(IRB EXEMPT) INST 1303: Global Analysis of Genetic Variability in New Mexicans with Colorectal Cancer:
A Pilot/Feasibility Study
INST 1116GI Colorectal AdvancedOpen Active2012-04-04(IRB EXEMPT) INST 1116: Effect of Obesity on Colon Cancer Incidence and Metastasis: a SEER Registry Analysis
INST 1204GI Colorectal AncillaryOpen Active2012-05-22INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
Alliance A021302GI Gastric AdvancedOpen Active2017-01-23Alliance A021302: Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
COG AHEP0731GI Hepatic AdjuvantOpen Active2010-01-13COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma
SWOG S9808AdministrativeOpen Active1998-09-12SWOG S9808 - Long Term Follow-up Protocol: An Administrative Tool
Pharm ICT-107-301Brain AdjuvantOpen Active2017-01-11ImmunoCellular ICT-107-301: A Phase III Randomized Double-blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma following Resection and Concomitant TMZ Chemoradiotherapy
COG ACNS0332Brain AdjuvantOpen Active2015-06-22COG ACNS0332: A Groupwide Phase III Study: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
COG ACNS0831Brain AdjuvantOpen Active2010-12-02COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
NCCTG N0577Brain AdvancedOpen Active2015-08-31NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Alliance A071401Brain AdvancedOpen Active2016-07-28Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations

UNM - Lovelace

Trial #TypeStudy StatusStatus DateTitle
31/05/2017Lung NSCLC Adjuvant1969-12-31Page -1 of 1
Total Studies:Lung NSCLC Adjuvant1969-12-31194
ECOG-ACRIN EA5142Lung NSCLC AdjuvantOpen Active2017-03-07ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)